MedTrace Logo

Effects of DPP4 Inhibition on COVID-19

NCT04341935 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2021-06-10

No results posted yet for this study

Summary

The purpose of this research is to see if the DPP4 inhibitor linagliptin, an oral medication commonly used to treat type 2 diabetes,can help with diabetes control and reduce the severity of the COVID-19 infection

Conditions

Interventions

DRUG

Linagliptin

5 mg Linagliptin administered by mouth once daily

DRUG

Insulin regimen

Standard of care insulin regimen as per hospital protocol

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Gianluca Iacobellis, MD PhD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-12-30
Completion
2021-12-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04341935 on ClinicalTrials.gov